No connection

Search Results

ABBV vs BFRI

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
BFRI
Biofrontera Inc.
BEARISH
Price
$0.86
Market Cap
$10.0M
Sector
Healthcare
AI Confidence
92%

Valuation

P/E Ratio
ABBV
163.63
BFRI
--
Forward P/E
ABBV
15.42
BFRI
-3.72
P/B Ratio
ABBV
-146.66
BFRI
-3.85
P/S Ratio
ABBV
6.5
BFRI
0.27
EV/EBITDA
ABBV
15.27
BFRI
-0.65

Profitability

Gross Margin
ABBV
71.46%
BFRI
64.41%
Operating Margin
ABBV
35.5%
BFRI
-89.84%
Profit Margin
ABBV
4.0%
BFRI
-47.28%
ROE
ABBV
137.96%
BFRI
-1191.73%
ROA
ABBV
9.59%
BFRI
-64.91%

Growth

Revenue Growth
ABBV
9.1%
BFRI
-22.5%
Earnings Growth
ABBV
-88.7%
BFRI
--

Financial Health

Debt/Equity
ABBV
--
BFRI
--
Current Ratio
ABBV
0.72
BFRI
1.15
Quick Ratio
ABBV
0.47
BFRI
0.51

Dividends

Dividend Yield
ABBV
3.05%
BFRI
--
Payout Ratio
ABBV
490.15%
BFRI
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
BFRI BEARISH

BFRI exhibits severe financial distress, reflected in a Piotroski F-Score of 1/9 (indicating weak financial health) and a lack of Altman Z-Score data, which raises red flags for potential bankruptcy risk. The company reports massive losses with a -47.28% profit margin, negative ROE (-1191.73%), and declining revenue (YoY -22.50%). Despite a strong gross margin (64.41%), operational inefficiencies and negative cash flows undermine sustainability. The stock trades at a deep discount (Price/Sales: 0.27), but this is not a value signal—rather, it reflects deteriorating fundamentals and investor skepticism. Analysts' 'strong_buy' recommendation appears disconnected from the underlying data.

Strengths
High gross margin (64.41%) suggests potential pricing power or low production costs
Recent 1-month price increase (+3.1%) indicates short-term momentum
Analyst consensus is 'strong_buy' despite poor fundamentals, suggesting potential catalyst expectations
Risks
Piotroski F-Score of 1/9 indicates extreme financial weakness and poor operational performance
Negative ROE (-1191.73%) and ROA (-64.91%) signal severe capital inefficiency and loss of shareholder value
Consistent earnings misses in the last 4 quarters (0/4 beats, average surprise -88.35%) reflect deteriorating execution

Compare Another Pair

ABBV vs BFRI: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Biofrontera Inc. (BFRI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile